Twist Bioscience (NASDAQ:TWST) SVP Sells 1,007 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) SVP Paula Green sold 1,007 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $136,347.80. Following the completion of the transaction, the senior vice president directly owned 105,625 shares in the company, valued at approximately $14,301,625. This trade represents a 0.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Paula Green also recently made the following trade(s):

• On Friday, October 2nd, Paula Green sold 10,088 shares of Twist Bioscience stock. The stock was sold at an average price of $188.88, for a total value of $1,905,421.44.
• On Monday, September 21st, Paula Green sold 294 shares of Twist Bioscience stock. The stock was sold at an average price of $165.49, for a total value of $48,654.06.

Twist Bioscience Trading Down 15.5%

Shares of NASDAQ:TWST traded down $22.05 during midday trading on Thursday, reaching $120.53. 3,084,289 shares of the company’s stock were exchanged, compared to its average volume of 1,763,809. The stock has a market cap of $7.56 billion, a price-to-earnings ratio of -54.29 and a beta of 2.25. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $219.71. The firm’s 50 day simple moving average is $152.59 and its two-hundred day simple moving average is $90.28. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same period in the previous year, the company earned $0.33 EPS. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TWST has been the subject of a number of recent analyst reports. Jefferies Financial Group began coverage on shares of Twist Bioscience in a research report on Thursday, October 8th. They set a “hold” rating and a $150.00 price target for the company. Piper Sandler upped their price objective on shares of Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a report on Wednesday, August 5th. BWS Financial reiterated a “sell” rating and issued a $45.00 target price on shares of Twist Bioscience in a report on Friday, September 18th. Canaccord Genuity Group upped their price target on Twist Bioscience from $120.00 to $205.00 and gave the stock a “buy” rating in a research note on Monday, October 12th. Finally, TD Cowen raised their price target on Twist Bioscience from $115.00 to $190.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $153.00.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors have recently bought and sold shares of the company. E. Ohman J or Asset Management AB acquired a new stake in shares of Twist Bioscience during the second quarter worth about $853,000. Allspring Global Investments Holdings LLC purchased a new position in shares of Twist Bioscience in the first quarter valued at approximately $22,563,000. Bank of America Corp DE boosted its stake in shares of Twist Bioscience by 46.3% in the first quarter. Bank of America Corp DE now owns 584,261 shares of the company’s stock valued at $27,764,000 after purchasing an additional 184,907 shares during the period. William Blair Investment Management LLC purchased a new position in shares of Twist Bioscience in the second quarter valued at approximately $223,722,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Twist Bioscience in the second quarter valued at approximately $8,215,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.